Connect with us

Technology

Navigating the Radiological Landscape: Insights into Radiotherapy and Nuclear Medicine Markets

Published

on

Advancements in AI (Artificial Intelligence) technology is poised to revolutionize radiotherapy, enhancing patient outcomes, and streamlining clinical workflows. Meanwhile, the nuclear medicine industry is witnessing rapid growth, driven by evolving therapeutic radiopharmaceuticals. These trends signal a transformative era for both fields.

BOSTON, July 22, 2024 /PRNewswire/ — According to the latest BCC Research study, the demand for “Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets” is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2029.”

This comprehensive report analyzes the global market for radiation therapy products (including systems, software, and services) and radiopharmaceuticals. By examining both quantitative and qualitative data, readers gain insights to assess the market, devise business strategies, and make informed decisions. BCC Research estimates market data for 2023 and forecasts values for 2024 through 2029. The report delves into radiation therapy market segmentation based on product, technology, techniques, system type, application, and region. Similarly, radiopharmaceuticals are segmented by product, application, production method, and region. Additionally, the report discusses industry growth drivers, restraints, opportunities, competitive landscapes, and emerging trends in these fields.

This report is particularly relevant now due to the significant challenges faced by the cancer care industry, such as rising costs, the necessity for personalized treatment, and a shortage of skilled healthcare staff. Healthcare professionals are increasingly seeking advanced radiotherapy devices that offer improved clinical quality and operational efficiency. There’s a growing demand for solutions that enable precise radiation delivery, efficient treatment planning, and effective data management to reduce treatment times and improve patient outcomes. Understanding these market dynamics and technological advancements is crucial for stakeholders to navigate the evolving landscape of cancer care effectively.

Please click here for more details on “The global market for radiation therapy products and radiopharmaceuticals Report.”

The following factors drive the global market for radiation therapy products and radiopharmaceuticals:

Rising Prevalence of Cancer and Chronic Conditions: The global increase in cancer and chronic diseases has heightened the demand for effective treatment options worldwide. Radiotherapy and radiopharmaceuticals have become pivotal in managing these conditions, offering crucial therapeutic avenues that complement surgery and chemotherapy.

Advances in Radiation Therapy Systems and Techniques: Innovations in radiation therapy planning and delivery systems have significantly improved treatment precision and patient outcomes. Techniques like intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery allow for highly targeted treatments, minimizing damage to surrounding healthy tissues while maximizing therapeutic effect.

Growing Demand in Developing Regions: Developing countries are experiencing rapid growth in healthcare infrastructure and awareness. As access to radiotherapy and nuclear medicine expands in these regions, there is a corresponding increase in demand for these technologies. This expansion is crucial in addressing healthcare disparities and improving treatment access for populations previously underserved.

Focus on Early Diagnosis and Screening: Early detection is critical in enhancing treatment success rates and improving patient outcomes. Nuclear medicine imaging, such as positron emission tomography (PET) scans, plays a pivotal role in the early diagnosis and staging of diseases. These technologies enable healthcare providers to detect and assess diseases at their earliest stages, facilitating timely intervention and personalized treatment strategies.

Trend Toward Precision Medicine: Precision medicine approaches are gaining prominence as healthcare shifts towards personalized treatment strategies. Radiopharmaceuticals, capable of targeting specific biological pathways and characteristics unique to individual patients, are at the forefront of this trend. They enable tailored therapies that maximize therapeutic efficacy while minimizing adverse effects, marking a significant advancement in cancer and chronic disease management.

Request a Sample Copy of The global market for radiation therapy products and radiopharmaceuticals Report.

Report Synopsis 

Report Metrics

Details

Base year considered

2023

Forecast Period considered

2024-2029

Base year market size

$16.1 billion

Market Size Forecast

$31.3 billion

Growth rate

CAGR of 12.3% for the forecast period of 2024-2029

Segment Covered

Segment, Product Type, Technology Type, Application, Production Method, and Region

Regions covered

North America, Europe, Asia-Pacific, and Rest of the World (RoW)

Key Market Drivers

 

Rising prevalence of cancer and other chronic conditions. Advances in radiation therapy planning and delivery systems and techniques. Increasing demand in developing regions. Focus on early diagnosis and screening. Trend towards precision medicine

 

Key Interesting Facts About the global market for radiation therapy products and radiopharmaceuticals:

AI Integration in Radiotherapy:

AI and machine learning advancements will lead to increased integration of these technologies into radiation therapy products and analysis software.This integration aims to enhance clinical outcomes by improving efficiency and accuracy.

Contouring and Segmentation:

AI plays a crucial role in contouring and segmenting tumors and organs at risk (OARs) within radiotherapy.Precise delineation of treatment areas is essential for effective radiation delivery.

Targeted Alpha Therapy (TAT):

TAT, also known as alpha radioimmunotherapy, is a rapidly evolving cancer treatment.It is expected to achieve a significant compound annual growth rate (CAGR) during the forecast period.

The global market for radiation therapy products and radiopharmaceuticals report includes in-depth data and analysis addressing the following important queries:

What is the projected market size and growth rate of the radiation therapy products and radiopharmaceuticals market?
•  The global radiation therapy products and radiopharmaceuticals market was estimated to be around $16.1 billion in 2023. The market is projected to reach $31.3 billion in 2029, growing at a CAGR of 12.3% during the forecast period.

What segments are covered in the market?
•  An in-depth analysis of the global radiation therapy products and radiopharmaceuticals market, including historical data and market projection on sales by technology type, product type, system type, application, and region.

By application type, which segment will dominate the market by the end of 2029?
•  By application type, the oncology segment is anticipated to dominate the market by the end of 2029.

Which product type market is growing fastest among all?
•  Therapeutic radiopharmaceuticals are the fastest growing market.

Some of the Key Market Players Are:

ACCURAY INC.CURIUMGE HEALTHCARENOVARTIS AGCARDINAL HEALTHELEKTALANTHEUSSIEMENS HEATHNIEERS AG

Directly Purchase a copy of the report with BCC Research.

For further information or to make a purchase, please get in touch with info@bccresearch.com.

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.

Contact Us
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
info@bccresearch.com,
+1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/navigating-the-radiological-landscape-insights-into-radiotherapy-and-nuclear-medicine-markets-302202486.html

SOURCE BCC Research LLC

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BlueNexus Technologies Unveils AquaX Hub at SIWW 2026 — AI Autonomous Operations Extended to Legacy Water Assets

Published

on

By

SINGAPORE, June 21, 2026 /PRNewswire/ — At Singapore International Water Week (SIWW) 2026, BlueNexus Technologies unveiled the global debut of AquaX Hub™ — a compact plug-and-play edge device that brings full AI-powered autonomous operation to standalone water equipment and legacy treatment plants. The launch drew sustained engagement from utilities, industrial operators and engineering firms.

The water sector confronts converging pressures: aging infrastructure, a critical shortage of skilled technicians, and relentless operational cost escalation. AquaX Hub™ answers these directly — extending the AI autonomous operation already proven plant-wide by AquaX Robot™ to a single asset, and delivering comparable monitoring and operational management without a control-system overhaul.

“The industry cannot hire its way out of this problem,” said Jack Zhang, CEO of BlueNexus Technologies. “AI autonomous operation is no longer a future concept — the barrier to entry is gone.”

The AquaX Ecosystem

BlueNexus has built the industry’s first fully integrated AI autonomous water operation platform, spanning three complementary pillars:

AquaX Robot™ is the flagship plant-wide AI agent, built on large language models with proprietary vision, acoustic and infrared multimodal sensing. It optimizes treatment processes 24/7 and predicts equipment failures. Live deployments show up to 90% reduction in on-site staffing, a 50% drop in equipment breakdowns, and approximately 35% lower O&M costs.

AquaX Hub™, making its global debut at SIWW 2026, is a lightweight edge terminal extending that capability to any water system. With an independent local processing module, it monitors and inspects equipment through multimodal sensing and runs a self-contained processing loop. The device integrates seamlessly with existing SCADA, cloud and enterprise platforms via standardized APIs.

i-WaterHub™, the company’s standardized modular treatment plant, operated autonomously by AquaX Robot, delivers 2,500 to 40,000 m³/day for municipal and industrial applications.

Market Momentum

SIWW 2026 convened nearly 500 exhibitors from over 65 countries. BlueNexus has identified priority markets for AquaX Hub™ in Southeast Asia, the Middle East and Africa. “The conversations this week have already translated into concrete business opportunities and we expect rapid deployment in the coming months.” Zhang confirmed.

About BlueNexus Technologies

BlueNexus Technologies is a Singapore-based water-technology company building intelligent, AI-operated systems for the world’s most water-intensive industries. We design and deliver modular water treatment infrastructure that is smarter to run, faster to deploy, and built to operate autonomously.

Web: www.bluenexus.tech

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/bluenexus-technologies-unveils-aquax-hub-at-siww-2026–ai-autonomous-operations-extended-to-legacy-water-assets-302805849.html

SOURCE BlueNexus Technologies

Continue Reading

Technology

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS

Published

on

By

With the presence of Emmanuel Macron and Narendra Modi, Prime Minister of India

PARIS, June 20, 2026 /CNW/ — From June 17 to 20, 2026 at Paris Porte de Versailles, VivaTech celebrated its 10th edition, surpassing the exceptional milestone of 200,000 visitors from 165 nationalities, with more than 15,000 startups present, 1,155 speakers and over 5 billion cumulative impressions on social media. Europe’s largest tech and innovation event has reached a new dimension, consolidating its status as an unmissable global gathering.

Exceptional speakers

VivaTech welcomed the greatest figures in global tech: Jeff Bezos (Amazon & Blue Origin), Dave Limp (Blue Origin), Bernard Arnault (LVMH), Henna Virkkunen (European Commission), Ekaterina Zaharieva (European Commission). Germany, Country of the Year 2026, was represented by a ministerial delegation, while India, AI Country Partner 2026, was led by Prime Minister Narendra Modi, as a continuation of the AI Summit in New Delhi.

Innovation and business at the heart of the event

More than 4,500 exhibitors, 61% of whom were international, showcased their latest innovations. Among the standout innovations: the smart contact lens by XPANCEO, the thought-controlled humanoid robot by Unitree x HABS, and the 3D-printed resorbable implants by Lattice Medical. New formats such as the Business Plaza and Investors Office Hours further accelerated business connections.

The VivaTech x Bloomberg Awards

For the first time, VivaTech presented the VivaTech x Bloomberg Awards, recognising the most influential figures in global tech, including Sir Tim Berners-Lee (Visionary Award), Joe Tsai (Leadership Award) and Yann LeCun (Momentum Award).

Innovation open to all

VivaTech also took over the Champs-Élysées on June 14th for an open-air technology showcase, before opening its doors to the general public on June 20th with astronaut Thomas Pesquet as guest star.

“This 10th edition was not a celebration of the 9 previous years, but the opening of a new decade full of promise.” — Maurice Lévy, Michèle Benbunan & François Bitouzet, VivaTech

See you from June 16 to 19, 2027 at Paris Expo Porte de Versailles for VivaTech 2027!

About VivaTech

VivaTech accelerates innovation by connecting startups, tech leaders, major companies, and investors responding to our world’s biggest challenges.  

Each year, over four exciting days in Paris, VivaTech creates Europe’s biggest startup and tech event, exploring the most disruptive topics in tech with world-premiere demos, launches, and conferences in a collaborative ecosystem. This is where business meets innovation. Join us for the eleventh edition of VivaTech 16-19 June 2027.

For more information go to our website at https://vivatech.com/media or follow us on social media @VivaTech.

Contact
press@vivatechnology.com 

Logo: https://mmx.prnewswire.com/media/MS1865564/VT_LOGO_EN.jpg
Photo : https://mmx.prnewswire.com/media/MS1869778/VivaTech_2026.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/vivatech-2026-celebrates-its-10th-anniversary-with-a-record-edition-surpassing-200-000-visitors-302805827.html

SOURCE VivaTech

Continue Reading

Technology

Pope Leo XIV embraces paediatric patients at CNAO in Pavia

Published

on

By

PAVIA, Italy, June 20, 2026 /PRNewswire/ — The National Center for Oncological Hadrontherapy (CNAO) served as the first stop today during Pope Leo XIV’s pastoral visit to the city of Pavia. His choice to begin his journey at this center reflects a profound commitment to fostering meaningful dialogue between advanced scientific progress and the alleviation of human suffering.

CNAO President Gianluca Vago and General Manager Sandro Rossi received His Holiness, illustrating the center’s distinctive capabilities. CNAO stands out as a unique reality in Italy, remaining one of the very few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions. The technological core of the facility is its synchrotron, a subatomic particle accelerator that generates ultra-high-precision beams to treat complex, inoperable and radioresistant tumours. This cutting-edge technology allows for the targeted eradication of diseased cells while meticulously preserving surrounding healthy tissues, drastically improving patients’ survival and quality of life.

Furthermore, CNAO is expanding its capabilities as a premier multi-center utilizing new ion species, like Helium, later Oxygen and Neon. Soon, treatments will incorporate the Leo Cancer Care upright positioning and imaging system. The immediate future also includes beginning therapies with a Hitachi dedicated proton accelerator and gantry and a BNCT system for metastatic diseases, equipped with an electrostatic accelerator produced by TAE Life Science. With these new technologies, CNAO will become one of the most technologically advanced center in the world.

To date, over six thousand individuals, including approximately three hundred children and adolescents, have benefited from these life-saving treatments.

During his visit, the Pope engaged with CNAO’s Board of Directors, a collaborative body uniting national universities, clinical institutions, and research centers. He also extended his heartfelt greetings to the two hundred employees of the center. These doctors, physicists, engineers, and researchers tirelessly operate the advanced technologies in the service of oncology patients.

The emotional pinnacle of the day was the Holy Father’s private gathering with a delegation of young children who underwent treatment. The paediatric patients and their families shared a deeply touching moment of closeness, receiving the Pope’s comforting embrace.

“The visit of Pope Leo XIV honours us and represents a moment of extraordinary human value”, stated CNAO President Gianluca Vago. “In his encyclical Magnifica Humanitas, the Holy Father emphasizes the necessity of a science that constantly safeguards the centrality of the person and directs technology toward the common good. In a time marked by global tensions, CNAO testifies daily how the incredible power of the atom can be used not to destroy, but to heal. The particle beams we utilize against disease are, symbolically, Rays of Hope, sharing and supporting the IAEA project bearing this name. The embrace the Holy Father reserved for our children reminds us that scientific research finds its most authentic purpose when it encounters listening, compassion, and hope”.

Photo – https://mma.prnewswire.com/media/2997869/Papa_al_Cnao_crediti_Andrea_Perotti.jpg
Logo – https://mma.prnewswire.com/media/2997643/CNAO_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/pope-leo-xiv-embraces-paediatric-patients-at-cnao-in-pavia-302805799.html

Continue Reading

Trending